Moreover, we have shown that combined immunohistochemical scores of MYC, BCL2 and BCL6 predict 5-year OS and 5-year PFS in DLBCL patients independent of the IPI following treatment with R-CHOP. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.